Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $11.54 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Cingulate Inc had its IPO on 2021-12-08 under the ticker symbol CING.
The company operates in the Healthcare sector and Biotechnology industry. Cingulate Inc has a staff strength of 15 employees.
Shares of Cingulate Inc opened at $1 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $0.91 - $1.03, and closed at $1.03.
This is a +0.98% increase from the previous day's closing price.
A total volume of 50,273 shares were traded at the close of the day’s session.
In the last one week, shares of Cingulate Inc have increased by +8.42%.
Cingulate Inc's Key Ratios
Cingulate Inc has a market cap of $11.54 million, indicating a price to book ratio of 1.2354 and a price to sales ratio of 0.
In the last 12-months Cingulate Inc’s revenue was $0 with a gross profit of $-8995280 and an EBITDA of $-17107708. The EBITDA ratio measures Cingulate Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cingulate Inc’s operating margin was 0% while its return on assets stood at -63.8% with a return of equity of -142.98%.
In Q4, Cingulate Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cingulate Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.67 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cingulate Inc’s profitability.
Cingulate Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.4476. Its price to sales ratio in the trailing 12-months stood at 0.
Cingulate Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $11.41 million
- Total Liabilities
- $7.01 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Cingulate Inc ended 2023 with $11.41 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.41 million while shareholder equity stood at $3.88 million.
Cingulate Inc ended 2023 with $0 in deferred long-term liabilities, $7.01 million in other current liabilities, 1131.00 in common stock, $-69408496.00 in retained earnings and $0 in goodwill. Its cash balance stood at $5.36 million and cash and short-term investments were $5.36 million. The company’s total short-term debt was $355,808 while long-term debt stood at $0.
Cingulate Inc’s total current assets stands at $7.87 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $762357.00 and inventory worth $0.
In 2023, Cingulate Inc's operating cash flow was $0 while its capital expenditure stood at $132630.4.
Comparatively, Cingulate Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Cingulate Inc stock is currently trading at $1.03 per share. It touched a 52-week high of $2.14 and a 52-week low of $2.14. Analysts tracking the stock have a 12-month average target price of $5.88.
Its 50-day moving average was $1.13 and 200-day moving average was $1.22 The short ratio stood at 0.51 indicating a short percent outstanding of 0%.
Around 2800.7% of the company’s stock are held by insiders while 146.9% are held by institutions.
Frequently Asked Questions About Cingulate Inc
Similar Industry Stocks (Biotechnology)
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company’s lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.